Phase III study of Pegapamodutide (OPK8800) for type 2 diabetes and obesity and NASH.
Latest Information Update: 28 Mar 2019
At a glance
- Drugs Pegapamodutide (Primary)
- Indications Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
Most Recent Events
- 28 Mar 2019 New trial record